1
|
Rusinova R, Koeppe RE, Andersen OS. A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics. ACTA ACUST UNITED AC 2015; 146:463-75. [PMID: 26573624 PMCID: PMC4664825 DOI: 10.1085/jgp.201511470] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 10/13/2015] [Indexed: 01/14/2023]
Abstract
Amiodarone is a widely prescribed antiarrhythmic drug used to treat the most prevalent type of arrhythmia, atrial fibrillation (AF). At therapeutic concentrations, amiodarone alters the function of many diverse membrane proteins, which results in complex therapeutic and toxicity profiles. Other antiarrhythmics, such as dronedarone, similarly alter the function of multiple membrane proteins, suggesting that a multipronged mechanism may be beneficial for treating AF, but raising questions about how these antiarrhythmics regulate a diverse range of membrane proteins at similar concentrations. One possible mechanism is that these molecules regulate membrane protein function by altering the common environment provided by the host lipid bilayer. We took advantage of the gramicidin (gA) channels' sensitivity to changes in bilayer properties to determine whether commonly used antiarrhythmics--amiodarone, dronedarone, propranolol, and pindolol, whose pharmacological modes of action range from multi-target to specific--perturb lipid bilayer properties at therapeutic concentrations. Using a gA-based fluorescence assay, we found that amiodarone and dronedarone are potent bilayer modifiers at therapeutic concentrations; propranolol alters bilayer properties only at supratherapeutic concentration, and pindolol has little effect. Using single-channel electrophysiology, we found that amiodarone and dronedarone, but not propranolol or pindolol, increase bilayer elasticity. The overlap between therapeutic and bilayer-altering concentrations, which is observed also using plasma membrane-like lipid mixtures, underscores the need to explore the role of the bilayer in therapeutic as well as toxic effects of antiarrhythmic agents.
Collapse
Affiliation(s)
- Radda Rusinova
- Department of Physiology and Biophysics and Department of Anesthesiology, Weill Cornell Medical College, New York, NY 10065 Department of Physiology and Biophysics and Department of Anesthesiology, Weill Cornell Medical College, New York, NY 10065
| | - Roger E Koeppe
- Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701
| | - Olaf S Andersen
- Department of Physiology and Biophysics and Department of Anesthesiology, Weill Cornell Medical College, New York, NY 10065
| |
Collapse
|
2
|
Fyhrquist F, Kurppa K, Huuskonen M, Koistinen A. Blood pressure and renin during treatment with pindolol. ACTA MEDICA SCANDINAVICA 2009; 202:55-60. [PMID: 899884 DOI: 10.1111/j.0954-6820.1977.tb16783.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Beta-receptor blocking drugs are known to decrease BP and plasma renin activity (PRA) in hypertensive patients. We treated 31 hypertensive patients with the beta-receptor blocking drug, pindolol, for 3 months. During the first month (mean daily dose 10 mg) and the second month (mean daily dose 14.2 mg) BP and PRA decreased. During the third month of pindolol therapy (mean daily dose 19.0 mg) 16 patients had an unexpected rise of BP towards control levels and PRA levels rose, too. The remaining 15 patients maintained a good antihypertensive drug effect and suppression of PRA. Pretreatment PRA was not related to BP reduction. The change in diastolic BP was not significantly related to that in PRA. The results indicate that low doses of pindolol,10-15 mg daily, will suffice in mild essential hypertension. An increasing frequency of partial drug resistance may be a result of unnecessarily high doses of pindolol.
Collapse
|
3
|
Frithz G. Once a day treatment of hypertension. ACTA MEDICA SCANDINAVICA. SUPPLEMENTUM 2009; 606:77-81. [PMID: 268934 DOI: 10.1111/j.0954-6820.1977.tb18033.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Two studies are presented on the possibility of treating hypertension with pindolol once daily. In the first one, patients already treated with multiple doses of pindolol, propranolol or alprenolol were shifted to single dose regime with pindolol, given in the morning. In most cases an adequate blood pressure control could be maintained on a dose of up to 20 mg pindolol. In the other study, previously untreated patients with mild to moderate hypertension were treated from the beginning with a single dose of pindolol. An adequate pressure control was also obtained in most of these patients with a dose not surpassing 20 mg pindolol once daily. In non-responders, the addition of a once daily dose of a diuretic resulted in an adequate pressure control. In both studies side-effects were few. The absence of sleep disturbances and beta-blocker induced bradycardia was particularly noteworthy.
Collapse
|
4
|
Abstract
Beta-adrenoceptor blocking agents are established as one of the principal classes of antihypertensive agents. Despite progressive refinements over the years, they still possess some unwanted effects, which limit their considerable value. In recent years a wide range of variations upon the beta-blocker theme has been developed. The full clinical advantages of the newer agents remain to be defined.
Collapse
Affiliation(s)
- D McAreavey
- Department of Cardiology, Royal Infirmary, Edinburgh, UK
| | | | | |
Collapse
|
5
|
van den Meiracker AH, Man in 't Veld AJ, van Eck HJ, Boomsma F, Schalekamp MA. Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 1988; 78:957-68. [PMID: 3048776 DOI: 10.1161/01.cir.78.4.957] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Comparison of the hemodynamic and hormonal effects of beta-adrenoceptor antagonists with different ancillary properties may help to clarify the antihypertensive mechanism of these drugs. Under strict basal conditions, the effects of acebutolol (400 mg b.i.d.), atenolol (100 mg b.i.d.), pindolol (10 mg b.i.d.), and propranolol (80 mg t.i.d.), were studied for the first 24 hours in 40 hypertensive patients. With pindolol, mean arterial pressure was reduced (p less than 0.05) 1 hour after administration, whereas the cardiac index and the systemic vascular resistance index did not change. With the other three drugs, the fall in mean arterial pressure was delayed 2-3 hours. With these drugs, the fall in mean arterial pressure was preceded by a rise in the resistance index, which compensated for the initial fall in cardiac index. With each drug, the decrements in mean arterial pressure were associated with parallel decrements in the resistance index, and percent changes in mean arterial pressure and the resistance index were always significantly (p less than 0.001) correlated. At the end of the 24-hour period, the four drugs shared an equal antihypertensive effect, which varied 14-17%. This was associated with a return of the cardiac index toward control values by acebutolol, atenolol, and propranolol treatment and a moderately increased cardiac index above pretreatment values (13%, p less than 0.01) with pindolol. The secondary rise in the cardiac index was inversely correlated (p less than 0.001) with the fall in mean arterial pressure with all four drugs. Plasma renin was maximally suppressed 2 hours after treatment, thus before any change in mean arterial pressure had occurred with acebutolol, atenolol, and propranolol. Pretreatment values of active renin and the reduction of mean arterial pressure 24 hours after administration were not correlated in any of the four groups. Despite the "vasodilator" action of the four drugs, plasma norepinephrine did not rise. Our data show that the main hemodynamic change that occurs at the time blood pressure falls after beta-adrenoceptor antagonism is vasodilation. Neither autoregulation of blood flow nor renin suppression can explain this vasodilator action. The absence of an increase in norepinephrine, despite vasodilation, suggests that beta-adrenoceptor antagonism interferes with sympathetic vasoconstrictor nerve activity. This effect may explain the vasodilator and antihypertensive potential of beta-adrenoceptor antagonists.
Collapse
Affiliation(s)
- A H van den Meiracker
- Department of Internal Medicine 1, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
| | | | | | | | | |
Collapse
|
6
|
Abstract
There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicating a diuretic; or contraindication e.g. asthma, and beta-adrenoceptor blocking drugs. beta-Adrenoceptor blocking drugs have the advantage of a long history and of possibly being cardioprotective following myocardial infarction, but they have not yet been established as primary preventive agents in hypertensive patients. The alpha-receptor blocking drugs have the advantage of favourably affecting lipid profile and blood pressure. Therefore, there may be advantages in the use of combined alpha- and beta-blockade. The diuretics, which have the advantage of being inexpensive, are widely used but long term metabolic effects, particularly hypokalaemia, cause concern. This is correctable by co-administration of a potassium sparing diuretic and often preventable by using low doses of the diuretic. Diet may be important as hypokalaemia appears to be less of a problem where potassium intake is high. Experience with calcium antagonists is widening but the use of converting enzyme inhibitors is more limited, and some physicians are less ready to use them as first choice in mild hypertension at present. Drugs like methyldopa, clonidine, the adrenergic neurone inhibitory drugs are now used more as reserve agents. More severe cases of hypertension may require drugs from 2 of the 3 major groups: beta-blocking drugs, vasodilators and diuretics. In some cases, drugs from each of these 3 groups will be required.
Collapse
Affiliation(s)
- B N Prichard
- Department of Clinical Pharmacology, University College London
| |
Collapse
|
7
|
Affiliation(s)
- B N Prichard
- Department of Clinical Pharmacology, University College London, Rayne Institute, England
| | | |
Collapse
|
8
|
van den Meiracker AH, Man in't Veld AJ, Schalekamp MA. Comparison of the onset of the antihypertensive action of pindolol and propranolol. A 24 h haemodynamic study. Br J Clin Pharmacol 1987; 24 Suppl 1:39S-44S. [PMID: 3326634 PMCID: PMC1386207 DOI: 10.1111/j.1365-2125.1987.tb03267.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
1. Haemodynamic changes during the onset of the antihypertensive action of pindolol, 10 mg twice daily, and propranolol, 80 mg three times daily, were studied for 24 h in two groups of 10 patients with uncomplicated essential hypertension. 2. Baseline haemodynamics were not different between the two groups. 3. Pindolol, with considerable intrinsic sympathomimetic activity (ISA) exerted its maximal antihypertensive efficacy within 3-4 after dosing (-15 +/- 3%, mean +/- s.e. mean, P less than 0.001). This effect was maintained for 24 h. 4. After propranolol, which is devoid of ISA, arterial pressure fell more gradually, but after 24 h the two drugs shared an equal antihypertensive effect. 5. Cardiac output rose after pindolol by 16 +/- 5% (P less than 0.01). It decreased transiently by 16 +/- 6% (P less than 0.01) 1-4 h after propranolol. At that time vascular resistance had risen by 18 +/- 5% (P less than 0.001). 6. The onset of the antihypertensive action of the two drugs was associated with reductions in vascular resistance. Since reflex vasoconstriction did not occur after pindolol, vascular resistance was always lower on this drug than on propranolol (-29 +/- 4%, P less than 0.001 vs -15 +/- 5%, P less than 0.01). 7. Cardiac filling pressures, pulmonary artery pressure and pulmonary vascular resistance did not change after pindolol but they rose after propranolol. 8. During the onset of the vasodilator and antihypertensive effects of the two beta-adrenoceptor blockers heart rate, stroke volume and cardiac output rose, despite cardiac beta-adrenoceptor blockade, suggesting a reduction of parasympathetic tone and an increase in venous return.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A H van den Meiracker
- Department of Internal Medicine I, University Hospital Dijkzigt, Erasmus University Rotterdam, The Netherlands
| | | | | |
Collapse
|
9
|
van den Meiracker AH, Man in 't Veld AJ, Ritsema van Eck HJ, Schalekamp MA. Systemic and renal vasodilation after beta-adrenoceptor blockade with pindolol: a hemodynamic study on the onset and maintenance of its antihypertensive effect. Am Heart J 1986; 112:368-74. [PMID: 2874735 DOI: 10.1016/0002-8703(86)90277-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Pindolol, a beta blocker with considerable partial agonist activity (PAA), was studied in 10 hypertensive subjects. The maximal fall in mean arterial pressure (MAP) was seen 3 to 4 hours after oral dosing with 10 mg of pindolol (-15 +/- 3%, mean +/- SEM). This was caused by a reduction in total peripheral resistance (TPR), which amounted to 25 +/- 4% after 24 hours. Cardiac output increased by 16 +/- 5%. Cardiac filling pressures and pulmonary artery pressure did not change. Increasing the dose of pindolol, from 5 mg twice a day to 15 mg twice a day over a 3-week period, caused no further change in MAP. After 3 weeks, the fall in MAP (-11 +/- 2%) was maintained by reduced TPR (-26 +/- 6%), whereas cardiac output and stroke volume were increased by 16 +/- 6% and 26 +/- 6%. Renal blood flow and glomerular filtration rate did not change. Beta blockers devoid of PAA lower cardiac output, whereas the elevated TPR in hypertension is unchanged. The hemodynamic profile of pindolol essentially differs from that of beta blockers devoid of PAA.
Collapse
|
10
|
Säkö S, Sotaniemi EA, Anttila M. Liver drug metabolism and blood pressure response to a lipophilic and hydrophilic beta blocker. Eur J Drug Metab Pharmacokinet 1986; 11:81-6. [PMID: 3770017 DOI: 10.1007/bf03189831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The role of liver drug metabolism on blood pressure (BP) response to a lipophilic (propranolol) and hydrophilic (sotalol) beta blocker in thirty hypertensive patients was studied. Ten patient treated with diuretics were classified according to plasma antipyrine clearance rate as rapid and slow metabolizers. They were first treated for one month with propranolol and then for one month with sotalol at equivalent dosage. Four patients, classified as rapid drug metabolizers had a better response to sotalol, 139 (SD 13)/92 (SD 6) mmHg, than to propranolol, 164 (21)/104 (10) mmHg. For the other six patients, with slow drug metabolism, the response to propranolol, 142 (8)/95 (8) mmHg was equal to sotalol, 143 (19)/93 (8) mmHg. Twenty patients were randomly divided into two groups. The patients in these groups were similar as to sex, age, body mass index, BP and rate of drug metabolism. The subjects in the first group were treated with propranolol and diuretic and those in the second with sotalol and diuretic. The BP response was equal in both groups, propranolol 147 (14)/96 (7) mmHg and sotalol 143 (12)/95 (9) mmHg after two years' follow-up. The rate of drug metabolism must be considered when evaluating response to lipophilic but not to hydrophilic beta blocker.
Collapse
|
11
|
Marks AD, Finestone A, Sobel E, Lanzilotti S. An office-based primary care trial of pindolol ('Visken') in essential hypertension. Curr Med Res Opin 1986; 10:296-307. [PMID: 3545686 DOI: 10.1185/03007998609111094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A large, open, multi-centre study was performed by physicians in general practice to evaluate the efficacy and tolerance of pindolol (10 to 20 mg per day) in the treatment of patients with essential hypertension. The records of 7324 patients who completed the 6-week protocol with pindolol alone or in combination with a diuretic were analyzed by computer. Substantial reductions in both systolic and diastolic blood pressure were obtained in the majority of patients regardless of age, sex or race. No difference in blood pressure response was found between patients taking diuretics concurrently and those on pindolol alone. Side-effects were generally not troublesome and a trend toward a reducing incidence of side-effects was noted in all patients as the duration of therapy increased. Black patients tended to complain of fewer side-effects than did white patients.
Collapse
|
12
|
van Zwieten PA, Timmermans PB. Brain levels and acute antihypertensive activity of beta-blockers. Eur J Clin Pharmacol 1985; 28 Suppl:13-9. [PMID: 2865143 DOI: 10.1007/bf00543704] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The penetration of beta-adrenoceptor blockers into the cerebrospinal fluid and into brain tissue is related to the lipophilicity of these drugs, as reflected by the partition coefficients between octanol and aqueous buffers. However, experimental techniques in animal models show no obvious relationships between the degree of brain penetration and the acute central antihypertensive effect of certain beta-blockers. This discrepancy is demonstrated convincingly by comparative experiments with atenolol and metoprolol. Both drugs are beta 1-selective blockers, and atenolol is highly polar, whereas metoprolol is lipophilic. Both these beta-blockers penetrate the CNS but to differing degrees. The experiments performed with these compounds support other studies described in the literature and do not suggest that there is a central mechanism which underlies the antihypertensive activity of beta-blockers.
Collapse
|
13
|
Abstract
Beta-adrenoceptor antagonists are effective in the management of patients with mild-to-moderate hypertension. Noncardioselective agents, cardioselective agents and beta blockers with intrinsic sympathomimetic activity (ISA) are equally effective, provided they are used in equipotent doses. Beta blockers can be used as first-line therapy in the management of hypertension and can be safely combined with diuretics, vasodilators, or both, for a better control of blood pressure. The exact mechanism by which beta blockers decrease blood pressure remains speculative, but they all reduce cardiac output during long-term therapy; drugs with ISA lower cardiac output and heart rate less than do drugs without ISA. Pharmacokinetic properties of beta blockers differ widely; drugs metabolized by the liver have shorter plasma half-lives than drugs primarily excreted by the kidneys. Although many of the side effects of various beta blockers are similar, differences in water and lipid solubility account for a higher incidence of central nervous system side effects with lipid-soluble drugs (such as propranolol and metoprolol) than with hydrophilic drugs (such as atenolol and timolol). The incidence of cold extremities has been reported to be less with drugs with ISA, and the incidence of bronchospasm less with cardioselective drugs. In the management of uncomplicated mild-to-moderate hypertension, all beta blockers are equally effective and produce less troublesome side effects than alternative antihypertensive agents. For effective therapy beta blockers can be used in 2 divided daily doses or even once daily.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
14
|
Ishizaki T, Oyama Y, Suganuma T, Sasaki T, Nakaya H, Shibuya T, Sato T. A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics. Br J Clin Pharmacol 1983; 16:17-25. [PMID: 6349668 PMCID: PMC1427944 DOI: 10.1111/j.1365-2125.1983.tb02138.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
The relationship between the oral dosage and plasma concentration of the long-acting cardioselective beta-adrenoceptor blocker atenolol and the antihypertensive response to the the degree of beta-adrenoceptor blockade and change in plasma renin activity (PRA) was evaluated in patients with mild-to-moderate essential hypertension in a double-blind, randomized, between-patient, dose-ranging (25, 50 or 100 mg once daily for 4 weeks) study. The optimum, or minimum, daily dose of atenolol to treat patients with mild-to-moderate hypertension was not clearly identified in this study. A between-treatment comparison did not demonstrate that all blood pressure falls were always less in the 25 mg group than in the other two groups. Calculation of beta-error or the power for the negative results between doses suggested that a large sample size is required to draw a conclusion that no dose-antihypertensive relationship of atenolol exists in the treatment of mild-to-moderate hypertension. A relatively flat plasma concentration-antihypertensive response relationship was observed. Steady-state plasma concentrations of atenolol were dose-related and renal drug clearance was well correlated with individual creatinine clearance. beta-adrenoceptor blockade was better correlated with plasma atenolol concentration. Correlations which were less strong were between plasma drug concentration and change in various blood pressures and between blood pressure falls and beta-adrenoceptor blockade. There was no relationship between the fall in blood pressure and change in PRA. Atenolol appeared to suppress PRA in an all-or-none fashion.
Collapse
|
15
|
Man in 't Veld AJ, Schalekamp MA. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol 1982; 13:245S-257S. [PMID: 6125175 PMCID: PMC1402134 DOI: 10.1111/j.1365-2125.1982.tb01922.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
1 A survey has been made of the literature on acute and long-term haemodynamic effects of ten different β-adrenoceptor antagonists. The β-adrenoceptor blockers are: pindolol, practolol, alprenolol, oxprenolol, acebutolol, penbutolol, metoprolol, atenolol, propranolol and timolol. The total numbers of patients included in this review are 396 patients in 41 acute studies and 410 patients in 36 long-term studies. 2 The effects of β-adrenoceptor blockers on the concentrations of plasma noradrenaline have also been reviewed. Ten studies including 110 patients on non-ISA-β-adrenoceptor blockers and eight studies including 116 patients on pindolol are presented. 3 In the acute studies (i.e. 15-90 min) arterial pressure was lowered by 1-7% and in the long-term studies (i.e. 3 days-5 years) by 6-17%. 4 The degree of cardio-depression induced by the various β-adrenoceptor blockers was inversely correlated with their pharmacologically defined quantity of intrinsic sympathomimetic activity (ISA) both in acute and in long-term studies. 5 In the acute studies the increments in peripheral vascular resistance were directly correlated with the degree of cardio-depression. This suggests that a fall in arterial pressure immediately after administration of a β-adrenoceptor blocker is prevented by increased vasoconstrictor nerve activity mediated through the arterial baroreflex. 6 The compensatory response of vascular resistance to cardio-depression was similar for β1-selective and non-selective blockers, thereby indicating that extra-junctional vascular β-receptors are relatively unimportant for maintaining basal vascular tone. 7 In the long-term studies the correlation between changes in cardiac output and changes in vascular resistance was shifted to a lower level of vascular resistance. This means that the onset of blood pressure reduction during β-adrenoceptor blockade was associated with a fall in vascular resistance at any level of cardiac output. Thus vascular resistance was higher during treatment with a non-ISA-β-adrenoceptor blocker than during treatment with an ISA-β-adrenoceptor blocker. 8 The level of vascular resistance ultimately attained during treatment with the various β-adrenoceptor blockers appears to be inversely related to their effects on plasma renin activity. 9 The concentration of noradrenaline in plasma rose by approximately 30% during treatment with non-ISA-β-adrenoceptor blockers and fell by more than 30% after pindolol. 10 There is evidence that under propranolol, which reduces cardiac output and hepatic blood flow, the plasma noradrenaline clearance is diminished. Since noradrenaline is mainly cleared from the circulation by the lungs and by the liver, and since pindolol has no effect on cardiac output and hepatic blood flow, one may expect the plasma noradrenaline clearance not to be diminished by pindolol. 11 The reported effects of β-adrenoceptor blockers on plasma noradrenaline may indicate that the release of neurotransmitter is diminished, but in the case of non-ISA-β-adrenoceptor blockers this effect is not reflected by a decreased concentration of noradrenaline in plasma, because its clearance is also reduced. 12 The hypotensive effect of β-adrenoceptor blockers appears to be independent of blockade of postjunctional cardiac-β-receptors, juxtaglomerular-β-receptors and extrajunctional vascular β-receptors. This indicates that blockade of β-receptors at other sites (i.e. centrally and/or prejunctionally) is more important.
Collapse
|
16
|
Clinical Pharmacology of Antihypertensive Drug Therapy. ARTERIAL HYPERTENSION 1982. [DOI: 10.1007/978-1-4612-5657-1_32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
17
|
Esler M, Jackman G, Leonard P, Skews H, Bobik A, Jennings G. Effect of propranolol on noradrenaline kinetics in patients with essential hypertension. Br J Clin Pharmacol 1981; 12:375-80. [PMID: 7295467 PMCID: PMC1401797 DOI: 10.1111/j.1365-2125.1981.tb01229.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
1 The rates of noradrenaline spillover to, and removal from, plasma were measured in ten patients with essential hypertension treated with propranolol, to ascertain if long-term administration of this drug reduces sympathetic nervous system tone. 2 The plasma clearance of noradrenaline fell with propranolol, leading to a small rise in the mean plasma noradrenaline concentration. Sympathetic nervous activity in treated patients cannot be reliably gauged from plasma noradrenaline values because these are distorted by the reduction in noradrenaline clearance. 3 There was no consistent effect on noradrenaline spillover rates, which fell in six patients, but rose in the remaining four. The magnitude of the antihypertensive response was unrelated to these changes in noradrenaline release. During propranolol treatment, noradrenaline spillover rates were in every case within the normal range, much higher than in patients treated with the known sympathetic nervous systems suppressant, clonidine. 4 The principal mode of antihypertensive action of propranolol is something often than central suppression of sympathetic tone or pre-synaptic inhibition of noradrenaline release.
Collapse
|
18
|
Andersson O, Berglund G, Descamps R, Thomis J. Sotalol and metoprolol comparison of their anti-hypertensive effect. Eur J Clin Pharmacol 1981; 21:87-92. [PMID: 7341284 DOI: 10.1007/bf00637506] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
28 patients, aged 35-62 years, with uncomplicated hypertension, entered a double-blind, crossover study, in which the effects of single daily doses of sotalol and metoprolol were compared. Both drugs exerted a clinically useful anti-hypertensive effect as monotherapy, or in combination with a thiazide diuretic. No significant difference in hypotensive effects was noted between the two beta-blocking agents, when the dose was titrated to an optimal clinical effect. Treatment with sotalol and metoprolol was associated with a clinically insignificant increase in serum uric acid concentration. The side-effects observed were few, and in only two cases was therapy discontinued. We regard both sotalol and metoprolol as useful anti-hypertensive drugs.
Collapse
|
19
|
Planz G, Planz R. Dissociation between duration of plasma catecholamine and blood pressure responses to beta-adrenergic blockade in normotensive subjects during physical exercise. Eur J Clin Pharmacol 1981; 19:83-8. [PMID: 6110540 DOI: 10.1007/bf00568393] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
20
|
Gugler R, Krist R, Raczinski H, Höffgen K, Bodem G. Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs. Br J Clin Pharmacol 1980; 10:337-43. [PMID: 6108780 PMCID: PMC1430092 DOI: 10.1111/j.1365-2125.1980.tb01769.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
1. Metoprolol (ME), pindolol (PI) and propranolol (PR) were studied in nine subjects at different doses and at 'maximum beta-adrenoceptor blockade' at a defined exercise load. Exercise tests were performed after each dosing period; isoprenaline stimulation was studied at the highest dose level. 2. ME and PR reduced heart rate at rest with most doses tested, while PI had no effect on resting heart rate. 3. Exercise heart rate was reduced with the smallest daily doses (ME 75 mg; PI 7.5 mg; PR 60 mg), and maximum reduction was from 163 to 116 beats/min (ME), 124 (PT) and 115 (PR) beats/min with daily doses of 242, 23 and 233 mg, respectively. 4. Resting blood pressure was not significantly affected by any beta-adrenoceptor blocker dose, but exercise induced blood pressure decreased from 166 to 130 (ME), 138 (PI) and 131 (PR) mm Hg, respectively. 5. Mean plasma concentrations at 'maximum beta-adrenoceptor blockade' were 158 (ME), 24 (PI) and 159 (PR) ng/ml without significant differences in the plasma level variation between beta-adrenoceptor blockers. 6. Isoprenaline doses required to increase heart rate by 30 beats/min were 3.8 microgram (control), 22 microgram (ME), 458 microgram (PI) and 200 microgram (PR), respectively. The differences may be due to different ratios of beta 1, beta 2 activity of the beta-adrenoceptor blockers tested.
Collapse
|
21
|
Bangah M, Jackman G, Bobik A. Determination of pindolol in human plasma by high-performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY 1980; 183:255-9. [PMID: 7400286 DOI: 10.1016/s0378-4347(00)81703-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
22
|
Haglund K, Collste P. Time course of blood pressure, pulse rate, plasma renin and metoprolol during treatment of hypertensive patients. Eur J Clin Pharmacol 1980; 17:321-8. [PMID: 6998708 DOI: 10.1007/bf00558443] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Eleven patients were treated for essential hypertension with metoprolol (Selokén) for more than three months. The time course of changes in blood pressure, pulse rate and plasma renin activity was studied during treatment with an oral maintenance dose of 100 mg twice daily. Significant decreases in pulse rate, diastolic blood pressure and plasma renin activity were observed even after the first dose. The plasma concentration of metoprolol reached equilibrium after the second dose. After the third dose there was no further significant change in blood pressure. There was a significant correlation (p < 0.001) between the initial (after three doses) and final (after > 90 days) effect of metoprolol on blood pressure (r = 0.86 and 0.91 for systolic and diastolic blood pressure change, respectively).
Collapse
|
23
|
Roux A, Aubert P, Guedon J, Flouvat B. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol 1980; 17:339-48. [PMID: 7418713 DOI: 10.1007/bf00558446] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
24
|
Deitchman D, Perhach JL, Snyder RW. Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharmacol 1980; 61:263-77. [PMID: 6102523 DOI: 10.1016/0014-2999(80)90128-4] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
25
|
|
26
|
Buckingham RE, Hamilton TC. beta-Adrenoceptor blocking drugs and hypertension. GENERAL PHARMACOLOGY 1979; 10:1-13. [PMID: 33100 DOI: 10.1016/0306-3623(79)90022-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
27
|
Martin MA, Phillips FC, Tucker GT, Smith AJ. Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol 1978; 14:383-90. [PMID: 367793 DOI: 10.1007/bf00716378] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
28
|
Lang R, Maxrath A, Laaser U, Meurer KA, Kaufmann W. [The importance of changes in whole-body balance of sodium and noradrenaline in essential hypertension (author's transl)]. KLINISCHE WOCHENSCHRIFT 1978; 56:1097-108. [PMID: 30856 DOI: 10.1007/bf01477131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In 22 patients with essential hypertension plasma levels and urine excretions of sodium and noradrenaline were studied before, during and after long-term beta-blockade with pindolol. The relation between mean blood pressure and the quotient of sodium-/noradrenaline-excretion changed during treatment (placebo r=-0.34; pindolol r=+0.31). During placebo there existed a significant (p is less than 0.03) correlation between blood pressure and sodium-excretion which disappeared during beta-blockade. No correlation between blood pressure and noradrenaline was seen during placebo, whereas during beta-blockade a significant (p is less than 0.003) correlation was observed. In contrast to the placebo period there was a significant positive correlation between sodium- and noradrenaline-excretion during long-term treatment with pindolol. It is concluded that whole-body balance of sodium and noradrenaline is an important factor in essential hypertension.
Collapse
|
29
|
Rahn KH, Gierlichs HW, Planz G, Planz R, Schols M, Stephany W. Studies on the effects of propanolol on plasma catecholamine levels in patients with essential hypertension. Eur J Clin Invest 1978; 8:143-8. [PMID: 99311 DOI: 10.1111/j.1365-2362.1978.tb00827.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The influence of the beta receptor blocking agent propranolol on plasma catecholamine concentrations was studied in eight patients with essential hypertension. The study was of single blind crossover design. Propranolol given in oral doses ranging from 60 to 240 mg daily for a period of 3 weeks decreased blood pressure and heart rate. The beta-adrenergic blocking agent caused plasma catecholamine levels to increase both at rest and during bicycle exercise. Chromatographical analysis showed that concentrations of noradrenaline as well as of adrenaline rose during treatment with propranolol. However, dopamine-beta-hydroxylase activity in plasma was not altered. Furthermore, the urinary excretion of noradrenaline, adrenaline and 4-hydroxy-3-methoxy mandelic acid did not change during beta receptor blockade. The results are compatible with the assumption that antihypertensive doses of propranolol by decreasing cardiac output cause an activation of the sympatho-adrenal system.
Collapse
|
30
|
Prichard BN. The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol 1978; 5:379-99. [PMID: 26370 PMCID: PMC1429347 DOI: 10.1111/j.1365-2125.1978.tb01644.x] [Citation(s) in RCA: 94] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
All beta-adrenoceptor blocking drugs that have been described share the common property of being competitive inhibitors. They differ in their associated properties, the presence or absence of cardioselectivity, membrane stabilizing activity, and partial agonist activity. Recently some beta-adrenoceptor blocking drugs have been reported which also possess alpha-adrenoceptor blocking activity. The associated properties have been used as a basis for classifying beta-adrenoceptor blocking drugs (Fitzgerald, 1969, 1972). The presence or absence of cardioselectivity is most useful for dividing beta-adrenoceptor blocking drugs. The non-selective drugs (Division I) can be further divided according to the presence or absence of intrinsic sympathomimetic activity (ISA) and membrane stabilizing activity (Fitzgerald's groups I-IV). Group I possess both membrane activity and ISA, e.g. alprenolol, oxprenolol, group II just membrane action, e.g. propanolol, group III ISA but no membrane action, e.g. pindolol. Fitzgerald placed pindolol in group I but should be placed in group III as it possesses a high degree of beta-adrenoceptor blocking potency in relation to its membrane activity (Prichard, 1974). Finally drugs in group IV have neither ISA nor membrane action, e.g. sotalol, timolol. The cardioselective drugs (Division II) can be similarly sub-divided into groups I-IV according to the presence or absence of ISA or membrane action (Fitzgerald grouped all these together as group V). Lastly there are new beta-adrenergic receptor blocking drugs which in addition have alpha- adrenergic receptor blocking properties (Division III).
Collapse
|
31
|
Sassard J, Pozet N, McAinsh J, Legheand J, Zech P. Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol 1977; 12:175-80. [PMID: 590303 DOI: 10.1007/bf00609856] [Citation(s) in RCA: 42] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The pharmacokinetics of atenolol, a new cardioselective beta-adrenoceptor blocking agent, were determined following both acute and chronic dosing in 33 hypertensive patients with widely differing levels of renal impairment. In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses. This value increased markedly in patients with renal insufficiency and the blood clearance of atenolol was found to have a significant correlation with the glomerular filtration rate. This demonstrated the importance of the kidneys in the elimination of the drug. After 8 weeks oral treatment with atenolol (100 mg twice daily) a significant decrease in blood pressure, heart rate and plasma renin activity was observed, but no correlation was established between the blood levels of atenolol and any of its pharmacodynamic effects. A positive correlation was found however between the anti-hypertensive action of atenolol and the pretreatment value of the plasma renin activity.
Collapse
|
32
|
Hansson BG, Dymling JF, Hedeland H, Hulthén UL. Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol. I. Effect on maximal working capacity, plasma catecholamines and renin, Urinary aldosterone, blood pressure and pulse rate under basal conditions. Eur J Clin Pharmacol 1977; 11:239-45. [PMID: 324771 DOI: 10.1007/bf00607671] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
33
|
Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, DeQuattro V. Mild high-renin essential hypertension. Neurogenic human hypertension? N Engl J Med 1977; 296:405-11. [PMID: 834210 DOI: 10.1056/nejm197702242960801] [Citation(s) in RCA: 412] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
To determine whether the elevated plasma renin activity in some cases of mild essential hypertension expresses sympathetic-nervous-system over-activity, we compared indexes of sympathetic activity in 16 patients with mild high-renin essential hypertension, 15 hypertensive patients with normal plasma renin activity and 20 normal subjects. Patients with elevated activity exhibited a raised plasma norepinephrine concentration (P less than 0.05), a greater fall in cardiac output with cardiac beta-adrenergic blockade by intravenous propranolol (P less than 0.01), reduction in total peripheral vascular resistance with alpha-adrenergic blockade produced by intravenous phentolamine (P less than 0.01), and reduction to normal of blood pressure by "total" autonomic blockade (atropine, propranolol and phentolamine). On psychometric testing, patients with high-renin hypertension, but not those with normal plasma renin activity, exhibited suppressed hostility (P less than 0.01), a behavioral pattern linked to increased sympathetic activity. The hypertension in these patients with high renin activity is neurogenic and possibly psychosomatic in origin.
Collapse
|
34
|
|
35
|
Abstract
Eleven beta-adrenergic receptor blocking agents and derivatives were evaluated for their ability to affect systolic arterial blood pressure and pulse rate in unanesthetized, male spontaneously hypertensive rats (SHRs) and normotensive Wistar Kyoto (WKY) controls. Animals ranged from 7 to 76 weeks of age. The subcutaneous injection of 5 and 45 mg/kg metoprolol in 52 to 64 week old SHRs and 45 mg/kg twice a day to 26 to 29 week old SHRs produced a significant decrease in blooc pressure. The subcutaneous injection of pindolol (0.1 and 1.0 mg/kg) produced a greater and more consistent depressor effect in mature SHRs. The subcutaneous administration of sotalol (100 mg/kg) and alprenolol (20 mg/kg) resulted in a depressor action which was significant 120 minutes after injection of the drug. In the doses used, propranolol, oxprenolol, 4-hydroxypropranolol and K9-1366 produced pressor effect in SHRs. Propranolol did not cause this pressor effect in prehypertensive (seven week old) SHRs. Practolol, dextro-propranolol and KO-1313 had no effect on blood pressure in the doses used. Propranolol, pindolol, metoprolol, dextro-propranolol, 4-hydroxypropranolol, practolol, oxprenolol, KO-1366 and KO-1313 produced no significant effects on blood pressure in normotensive WKY controls in the doses tested. Placing oral doses of 160 mg/kg/day of metoprolol in the drinking water for seven days significantly lowered blood pressure in 14 week old SHRs previously exposed to ineffective doses of 77 mg/kg/day for 24 days. The administration of oral doses of oxprenolol (40 mg/kg/day) in drinking water for three weeks had a slight but insignificant pressor effect. Smaller doses of metoprolol (15 and 39 mg/kg/day for three to four weeks) and practolol (70 to 85 mg/kg/day for two weeks) had no effect on 52 week old SHRs. Oral doses of pindolol, metoprolol, practolol and oxprenolol had no significant effect on blood pressure in WKY controls. There was no clear relationship between the effects of the drugs on blood pressure and their ability to affect the pulse rate. Similarly, there did not appear to be any consistent relationship between the potency of the beta-blocking drug and the blood pressure lowering action. In addition, neither cardioselective beta-blockade nor sympathomimetic properties allowed the prediction of blood pressure responses to the administration of those agents possessing these features. Although SHRs provide a valuable model of human essential hypertension, the variable effects reported here and elsewhere in the literature require caution as to the applicability and usefulness of testing and evaluating beta-adrenergic blocking drugs for theri potential anti-hypertensive effects in this particular form of experimental hypertension.
Collapse
|
36
|
Zacest R. The vasodilator--beta-blocker interaction--some determinants of its clinical success. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE 1976; 6:65-76. [PMID: 14625 DOI: 10.1111/j.1445-5994.1976.tb03339.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A number of structurally dissimilar compounds, sharing the ability to induce vasodilatation have come into clinical usefulness as antihypertensive drugs. Their successful utilisation often depends critically on an appropriate combination with diuretics and beta-blockers. Beta-blockers can specifically inhibit the reflex cardiac stimulation which otherwise may limit the tolerability and haemodynamic value of these drugs. A synergistic antihypertensive effect has been demonstrated with hydrallazine and propranolol and possibly exists with other combinations. Generally, vasodilators are not first-line drugs in chronic therapy but are best added to beta-blockers. Variations of the dose-response and the time-course of effect are stressed as being important determinants of a successful interaction.
Collapse
|
37
|
Abstract
The beta-adrenergic blocking drug pindolol has been used in the treatment of hypertension, using one single dose per day, given in the morning. 16 patients with mild to moderate hypertension were treated with doses which were increased if necessary up to 20 mg, and 14 patients achieved an adequate level of blood-pressure control. The trial was carried out as a single-blind cross-over study. The study shows that pindolol, a non-selective beta-blocker of high potency, may be given once daily as a hypotensive, offering advantages both for patients and physicians. Side-effects were infrequent.
Collapse
|
38
|
Oates HF. Antihypertensive action of propranolol: Dr Oates writes. Clin Exp Pharmacol Physiol 1975. [DOI: 10.1111/j.1440-1681.1975.tb01849.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|